|
1
|
DeVita VT Jr and Chu E: A history of
cancer chemotherapy. Cancer Res. 68:8643–8653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sawyers C: Targeted cancer therapy.
Nature. 18:294–297. 2004. View Article : Google Scholar
|
|
3
|
Manning G, Whyte DB, Martinez R, Hunter T
and Sudarsanam S: The protein kinase complement of the human
genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Prenzel N, Fischer OM, Steit S, Hart S and
Ullrich A: The epidermal growth factor receptor family as a central
element for cellular signal transduction and diversification.
Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slichenmyer WJ and Fry DW: Anticancer
therapy targeting the erbB family of receptor tyrosine kinases.
Semin Oncol. 28(5 Suppl 16): 67–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith LA, Cornelius VR, Plummer CJ, Levitt
G, Verrill M, Canney P and Jones A: Cardotoxicity of anthracycline
agents for the treatment of cancer: Systematic review and
meta-analysis of randomized controlled trails. BMC Cancer.
10:3372010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Dalen EC, Michiels EM, Caron HN and
Kremer LC: Different anthracycline derivates for reducing
cardiotoxicity in cancer patients. Cochrane Database Syst Rev.
CDOO50062010.
|
|
8
|
Ewer MS and Ewer SM: Cardiotoxicity of
anticancer treatments: What the cardiologist needs to know. Nat Rev
Cariol. 7:564–575. 2010. View Article : Google Scholar
|
|
9
|
Billingham ME, Mason JW, Bristow MR and
Daniels JR: Anthracycline cardiomyopathy monitored by morphologic
changes. Cancer Treat Rep. 62:865–872. 1978.PubMed/NCBI
|
|
10
|
Bristow MR, Thompson PD, Martin RP, Mason
JW, Billingham ME and Harrison DC: Early anthracyline
cardiotoxicity. Am J Med. 65:823–832. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification for the HER-2/new oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schuell B, Gruenberger T, Scheithauer W,
Zielinski Ch and Wrba F: HER 2/new protein expression in colorectal
cancer. BMC Cancer. 6:1232006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Latif Z, Watters AD, Bartlett JM,
Underwood MA and Aitchison M: Gene amplification and overexpression
of HER2 in renal cell carcinoma. BJU Int. 89:5–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jelovac D and Emens LA: HER2-directed
therapy for metastatic breast cancer. Oncology (Williston Park).
27:166–175. 2013.PubMed/NCBI
|
|
15
|
Cardinale D, Colombo A, Torrisi R, Sandri
MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S and
Dessanai MA: Trastuzumab-induced cardiotoxicity: Clinical and
prognostic implications of troponin I evaluation. J Clin Oncol.
28:3910–3916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chu TF, Rupnick MA, Kerkela R, Dallabrida
SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F and
Desai J: Cardiotoxicity associated with tyrosine kinase inhibitor
sunitinib. Lancet. 370:2011–2019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shaikh AY and Shih JA:
Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep. 9:117–27.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seidman A, Hudis C, Pierri MK, Shak S,
Paton V, Ashby M, Murphy M, Stewart SJ and Keefe D: Cardiac
dysfunction in the trastuzumab clinical trials experience. J Clin
Oncol. 20:1215–1221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J and Pegram
M: Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guarneri V, Lenihan DJ, Velaro V, Durand
JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi
GN and Esteva FJ: Long-term cardiac tolerability of trastuzumab in
metastatic breast cancer: The M.D. Anderson cancer center
experience. J Clin Oncol. 24:4107–4115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ewer MS, Vooletich MT, Durand JB, Wood ML,
Davis JR, Valero V and Lenihan DJ: Reversibility of
trastuzumab-related cardiotoxicity: New insights based on clinical
course and response to medical treatment. J Clin Oncol.
23:7820–7826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Halyard MY, Pisansky TM, Dueck AC, Suman
V, Pierce L, Solin L, Marks L, Davidson N, Martino S and Kaufman P:
Radiotherapy and adjuvant trastuzumab in operable breast cancer:
Tolerability and adverse event data from the NCCTG phase III trial
N9831. J Clin Oncol. 27:2638–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garratt AN, Ozcelik C and Birchmeier C:
ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med.
13:80–86. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Negro A, Brar BK and Lee KF: Essential
roles of Her2/erbB2 in cardiac development and function. Recent
Prog Horm Res. 59:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa
S, Liu Y, Peterson KL, Chen J, Kahn R and Condorelli G: ErbB2 is
essential in the prevention of dilated cardiomyopathy. Nat Med.
8:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozcelik C, Erdmann B, Pilz B, Wettschureck
N, Britsch S, Hübner N, Chien KR, Birchmeier C and Garratt AN:
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes
leads to dilated cardiomyopathy. Pro Natl Acad Sci USA.
99:8880–8885. 2002. View Article : Google Scholar
|
|
27
|
Burris HA III, Hurwitz HI, Dees EC,
Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer
B, Jones SF, et al: Phase I safety, pharmacokinetics, and clinical
activity study of lapatinib (GW572016), a reversible dual inhibitor
of epidermal growth factor receptor tyrosine kinases, in heavily
pretreated patients with metastatic carcinomas. J Clin Oncol.
23:5305–5313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jaqiello-Gruszfeld A, Crown J, Chan A and
Kaufman B: Lapatinib plus capecitabine for HER2-positive advanced
breast cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gianni L, Lladó A, Bianchi G, Cortes J,
Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A,
Goeminne JC, et al: Open-label, phase II, multicenter, randomized
study of the efficacy and safety of two dose levels of peruzumab, a
human epidermal growth factor receptor 2 dimerization inhibitor, in
patients with human epidermal growth factor receptor 2-negative
metastatic breast cancer. J Clin Oncol. 28:1131–1137. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perez EA, Koehler M, Byrne J, Preston AJ,
Rappold E and Ewer MS: Cardiac safety of lapatinib: Pooled analysis
of 3689 patients enrolled in clinical trials. Mayo Clin Proc.
83:679–686. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fedele C, Riccio G, Malara AE, D'Alessio G
and De Lorenzo C: Mechanisms of cardiotoxicity associated with
ErbB2 inhibitors. Breast Cancer Res Treat. 134:595–602. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clynes RA, Towers TL, Presta LG and
Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity
against tumor targets. Nat Med. 6:443–446. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gennari R, Menard S, Fagnoni F, Ponchio L,
Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C and
Gibelli N: Pilot study of the mechanism of action of preoperative
trastuzumab in patients with primary operable breast tumors
overexpressing HERS2. Clin Cancer Res. 10:5650–5655. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Cutsem E, Lambrechts D, Prenen H, Jain
RK and Carmeliet P: Lessons from the adjuvant bevacizumab trial on
colon cancer: What next? J Clin Oncol. 29:1–4. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jardim DL, de Gagliato DM, Ribeiro KB,
Shimada AK and Katz A: Bevacizumab as first-line therapy in
advanced non-small-cell-lung cancer: A Brazillian center
experience. Drugs R D. 12:207–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rini BI: Vascular endothelial growth
factor-targeted therapy in renal cell carcinoma: Current status and
future directions. Clin Cancer Res. 13:1098–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scappacticci FA, Skillings JR, Holden SN,
Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Kolmangren
E, Wang J and Hurwitz H: Arterial thromboembolic events in patients
with metastatic carcinoma treated with chemotherapy and
bevacizumab. J Natl Cancer Inst. 99:1232–1239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hurwitz HI, Fehrenbacher L, Hainsworth JD,
Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and
Kabbinavar F: Bevacizumab in combination with fluorouracil and
leucovorin: An active regimen for first-line metastatic colorectal
cancer. J Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Miller KD, Chap LI, Holmes FA, Cobleigh
MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD
and Sing AP: Randomized phase III trial of capecitabine compared
with bevacizumab plus capecitabine in patients with previously
treated metastatic breast cancer. J Clin Oncol. 23:792–799. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Johnson DH, Fehrenbacher L, Novotny WF,
Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III,
Gaudreault J, Damico LA, et al: Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or
metastatic non-small-lung cancer. J Clin Oncol. 22:2184–2191. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hurwitz H and Saini S: Bevacizumab in the
treatment of metastatic colorectal cancer: Safety profile and
management of adverse events. Semin Oncol. 33(5 Suppl 10): S26–S34.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S
and Holmgren E: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pande A, Lombardo J, Spangenthal E and
Javle M: Hypertension secondary to anti-angiogenic therapy:
Experience with bevacizumab. Anticancer Res. 27:3465–3470.
2007.PubMed/NCBI
|
|
44
|
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW,
Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA and Ewer
MS: Cardiovascular complications of cancer therapy: Diagnosis,
pathogenesis and management. Circulation. 109:3122–3131. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
D'Adamo DR, Anderson SE, Albritton K,
Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H and Maki RG: Phase
II study of doxorubicin and bevacizumab for patients with
metastatic soft-tissue sarcomas. J Clin Oncol. 23:7135–7142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Karp JE, Gojo I, Pili R, Gocke CD, Greer
J, Guo C, Qian D, Morris L, Tidwell M and Chen H: Targeting
vascular endothelial growth factor for relapsed and refractory
adult acute myelogenous leukemias: Therapy with sequential
1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Clin Cancer Res. 10:3577–3585. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nalluri SR, Chu D, Keresztes R, Zhu X and
Wu S: Risk of venous thromboembolism with the angiogenesis
inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA.
300:2277–2285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Laitinen M, Zachary I, Breier G, Pakkanen
T, Häkinen T, Luoma J, Abedi H, Risau W, Soma M, Laakso M, et al:
VEGF gene transfer reduces intimal thickening via increased
production of nitric oxide in carotid arteries. Hum Gene Ther.
8:1737–1744. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Levy BI, Ambrosio G, Pries AR and
Struijker-Boudier HA: Microcirculation in hypertension: A new
target for treatment? Circulation. 104:735–740. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hesser BA, Liang XH, Camenisch G, Yang S,
Lewin DA, Scheller R, Ferrara N and Gerber HP: Down syndrome
critical region protein 1 (DSCR1), a novel VEGF target gene that
regulates expression of inflammatory markers on activated
endothelial cells. Blood. 104:149–158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kuenen BC, Levi M, Meijers JC, Kakkar AK,
van Hinsbergh VW, Kostense PJ, Pinedo HM and Hoekman K: Analysis of
coagulation cascade and endothelial cell activation during
inhibition of vascular endothelial growth factor/vascular
endothelial growth factor receptor pathway in cancer patients.
Arterioscler Thromb Vasc Biol. 22:1500–1505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Whittle BJ, Moncada S and Vane JR:
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1
and D2 on platelet aggregation in different species.
Prostaglandins. 16:373–388. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Izumiya Y, Shiojima I, Sato K, Sawyer DB,
Colucci WS and Walsh K: Vascular endothelial growth factor blockade
promotes the transition from compensatory cardiac hypertrophy to
failure in response to pressure overload. Hypertension. 47:887–893.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cheng H and Force T: Why do kinase
inhibitors cause cardiotoxicity and what can be done about it? Prog
Cariovasc Dis. 53:114–120. 2010. View Article : Google Scholar
|
|
55
|
Cheng H and Force T: Molecular mechanisms
of cardiovascular toxicity of targeted cancer therapeutics. Circ
Res. 106:21–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kerkela R, Woulfe KC, Durand JB, Vagnozzi
R, Kramer D, Chu TF, Beahm C, Chen MH and Force T:
Sunitinib-induced cardiotoxicity is mediated by off-target
inhibition of AMP-activated protein kinase. Clin Transl Sci.
2:15–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kerkela R, Grazette L, Yacobi R, Illiescu
C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S and Clubb FJ:
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Nat Med. 12:908–16. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
58
|
Talpaz M, Shah NP, Kantarjian H, Donato N,
Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C and Bleickardt
E: Dasatinib in imatinib-resistant Philadelphia chromosome-positive
leukemias. N Engl J Med. 354:2531–2541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Deming PB, Schafer ZT, Tashker JS, Potts
MB, Deshmukh M and Kornbluth S: Bcr-Abl-mediated protection from
apoptosis downstream of mitochondrial cytochrome c release.
Mol Cell Biol. 24:10289–10299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Beininger M, Buchdunger E and Druker BJ:
The development of imatinib as a therapeutic agent for chronic
myeloid leukemia. Blood. 105:2640–2653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cohen MH, Williams G, Johnson JR, Duan J,
Gobburu J, Rahman A, Benson K, Leighton J, Kim SK and Wood R:
Approval summary for imatinib mesylate capsules in the treatment of
chronic myelogenous leukemia. Clin Cancer Res. 8:935–942.
2002.PubMed/NCBI
|
|
62
|
Atallah E, Durand JB, Kantarjian H and
Cortes J: Congestive heart failure is a rare event in patients
receiving imatinib therapy. Blood. 110:1233–1237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hatfield A, Owen S and Pilot PR: In reply
to ‘Cardiotoxicity of the cancer therapeutic agent imatinib
mesylate’. Nat Med. 13:13; author reply 15–16. 2007. View Article : Google Scholar
|
|
64
|
Rosti G, Martinelli G and Baccarani M: In
reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib
mesylate’. Nat Med. 13:15; author reply 15–16. 2007. View Article : Google Scholar
|
|
65
|
Gambacorti-Passerini C, Tornaghi L,
Franceschino A, Piazza R, Corneo G and Pogliani E: In reply to
‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’.
Nat Med. 13:13–14; author reply 15–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Atallah E, Kantarjian H and Cortes J: In
reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib
mesylate’. Nat Med. 13:14; author reply 15–16. 2007. View Article : Google Scholar
|
|
67
|
Fernández A, Sanguino A, Peng Z, Crespo A,
Ozturk E, Zhang X, Wang S, Bornmann W and Lopez-Berestein G:
Rational drug redesign to overcome drug resistance in cancer
therapy: Imatinib moving target. Cancer Res. 67:4028–4033. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Demetri GB: Structural reengineering of
imatinib to decrease cardiac risk in cancer therapy. J Clin Invest.
117:3650–3653. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bearzi C, Rota M, Hosoda T, Tillmanns J,
Nascimbene A, De Angelis A, Yasuzawa-Amano S, Trofimova I, Siggins
RW and Lecapitaine N: Human cardiac stem cells. Proc Natl Acad Sci
USA. 104:14068–14073. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ghoreschi K, Laurence A and O'Shea JJ:
Selectivity and therapeutic inhibition of kinases: To be or not to
be? Nat Immunol. 10:356–360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
U.S. Food Drug Administration FDA approves
new treatment for gastrointestinal and kidney cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108583.htmAccessed.
January 26–2006
|
|
72
|
Young E, Miele L, Tucker KB, Huang M,
Wells J and Gu JW: SU11248, a selective tyrosine kinases inhibitor
suppresses breast tumor angiogenesis and growth via targeting both
tumor vasculature and breast cancer cells. Cancer Biol Ther.
10:703–711. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cell.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pal SK, Figlin RA and Yu H: Deciphering
the anticancer mechanisms of sunitinib. Cancer Biol Ther.
10:712–714. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Telli ML, Witteles RM, Fisher GA and
Srinivas S: Cardiotoxicity associated with the cancer therapeutic
agent sunitinib malate. Ann Oncol. 19:1613–1618. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Motzer RJ, Hutson TE, Tomczk P, Michaelson
MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C and Kim
ST: Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomized controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Edelberg JM, Lee SH, Kaur M, Tang L, Feirt
NM, McCabe S, Bramwell O, Wong SC and Hong MK: Platelet-derived
growth factor-AB limits the extent of mycocardial infarction in a
rat model: Feasibility of restoring impaired angiogenic capacity in
the aging heart. Circulation. 105:608–613. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chintalgattu V, Ai D, Langley RR, Zhang J,
Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, et al:
Cardiomyocyte PDGFR-beta signaling is an essential component of the
mouse cardiac response to load-induced stress. J Clin Invest.
120:472–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rini BI, Cohen DP, Lu DR, Chen I,
Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ:
Hypertension as a biomarker of efficacy in patients with metastatic
renal cell carcinoma treated with sunitinib. J Natl Cancer Inst.
103:763–773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fleisher LA, Fleischmann KE, Auerbach AD,
Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman
MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson
A, Ting HH, Uretsky BF and Wijeysundera DN: American College of
Cardiology; American Heart Association: 2014 ACC/AHA guideline on
perioperative cardiovascular evaluation and management of patients
undergoing noncardiac surgery: a report of the American College of
Cardiology/American Heart Association Task Force on practice
guidelines. J Am Coll Cardiol. 64:e77–e137. 2014. View Article : Google Scholar : PubMed/NCBI
|
